ABACAVIR SULFATE AND LAMIVUDINE Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Abacavir Sulfate And Lamivudine, and when can generic versions of Abacavir Sulfate And Lamivudine launch?
Abacavir Sulfate And Lamivudine is a drug marketed by Aurobindo Pharma, Aurobindo Pharma Ltd, Cipla, Laurus, Lupin Ltd, Teva Pharms Usa, and Zydus Pharms. and is included in seven NDAs.
The generic ingredient in ABACAVIR SULFATE AND LAMIVUDINE is abacavir sulfate; lamivudine. There are twelve drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Abacavir Sulfate And Lamivudine
A generic version of ABACAVIR SULFATE AND LAMIVUDINE was approved as abacavir sulfate; lamivudine by CIPLA on March 28th, 2017.
Summary for ABACAVIR SULFATE AND LAMIVUDINE
| US Patents: | 0 |
| Applicants: | 7 |
| NDAs: | 7 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Clinical Trials: | 8 |
| Patent Applications: | 201 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ABACAVIR SULFATE AND LAMIVUDINE at DailyMed |
Recent Clinical Trials for ABACAVIR SULFATE AND LAMIVUDINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| ViiV Healthcare | Phase 4 |
| Gilead Sciences | Phase 3 |
| GlaxoSmithKline | Phase 4 |
Pharmacology for ABACAVIR SULFATE AND LAMIVUDINE
Anatomical Therapeutic Chemical (ATC) Classes for ABACAVIR SULFATE AND LAMIVUDINE
US Patents and Regulatory Information for ABACAVIR SULFATE AND LAMIVUDINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 206151-001 | Mar 28, 2017 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Zydus Pharms | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 208990-001 | Nov 15, 2018 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Laurus | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 216332-001 | Jul 25, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Aurobindo Pharma Ltd | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 090159-001 | Nov 15, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Cipla | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 091144-001 | Mar 28, 2017 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
